Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$6.48 USD
-0.21 (-3.14%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.47 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 61 - 80 ( 366 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in South Korean COVID-19 Vaccine Trial; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to Sell - Still Unimpressed with INO-4800''s Ability to Compete
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-4800 Phase 1 Data; Operation Warp Speed Selection; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Recent Run Leaves Uncertain Upside; Downgrade to Neutral Without PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Korean COVID-19 DNA Vaccine Trial Start Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-4800 - Manufacturing Snag with VGXI; Trump Admin Excludes from List
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive COVID-19 DNA Vaccine Preclinical Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Most of These COVID-19 Vaccine Results Are Over Two Months Old
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ONCY and INO: ASCO 2020 Abstracts Relevant to Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-5401 Shows Glioblastoma Survival Advantage at 12 Months; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financial Results Reported; Glioblastoma Data Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20: Transformative 2020 Catalysts Coming, Lowering PT to $11 From $13
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Vaccine Program Acceleration Efforts Evident; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Vaccine Manufacturing Expansion Funding; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MERS Vaccine INO-4700 Shows Promise - Downgrading to Neutral on Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-4800 COVID-19 Trial Enrollment Completion.
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R